vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and SOLAREDGE TECHNOLOGIES, INC. (SEDG). Click either name above to swap in a different company.
SOLAREDGE TECHNOLOGIES, INC. is the larger business by last-quarter revenue ($335.4M vs $247.1M, roughly 1.4× ANI PHARMACEUTICALS INC). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs -39.4%, a 50.5% gap on every dollar of revenue. On growth, SOLAREDGE TECHNOLOGIES, INC. posted the faster year-over-year revenue change (70.9% vs 29.6%). SOLAREDGE TECHNOLOGIES, INC. produced more free cash flow last quarter ($43.3M vs $29.1M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 28.1%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
SolarEdge Technologies, Inc. is an Israeli company that developed a DC optimized inverter system.
ANIP vs SEDG — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $335.4M |
| Net Profit | $27.5M | $-132.1M |
| Gross Margin | — | 22.2% |
| Operating Margin | 14.1% | -14.4% |
| Net Margin | 11.1% | -39.4% |
| Revenue YoY | 29.6% | 70.9% |
| Net Profit YoY | 367.5% | 54.0% |
| EPS (diluted) | $1.14 | $-2.21 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $335.4M | ||
| Q3 25 | $227.8M | $340.2M | ||
| Q2 25 | $211.4M | $289.4M | ||
| Q1 25 | $197.1M | $219.5M | ||
| Q4 24 | $190.6M | $196.2M | ||
| Q3 24 | $148.3M | $235.4M | ||
| Q2 24 | $138.0M | $265.4M | ||
| Q1 24 | $137.4M | $204.4M |
| Q4 25 | $27.5M | $-132.1M | ||
| Q3 25 | $26.6M | $-50.1M | ||
| Q2 25 | $8.5M | $-124.7M | ||
| Q1 25 | $15.7M | $-98.5M | ||
| Q4 24 | $-10.3M | $-287.4M | ||
| Q3 24 | $-24.2M | $-1.2B | ||
| Q2 24 | $-2.3M | $-130.8M | ||
| Q1 24 | $18.2M | $-157.3M |
| Q4 25 | — | 22.2% | ||
| Q3 25 | — | 21.2% | ||
| Q2 25 | — | 11.1% | ||
| Q1 25 | — | 8.0% | ||
| Q4 24 | — | -57.2% | ||
| Q3 24 | — | -309.1% | ||
| Q2 24 | — | -4.1% | ||
| Q1 24 | — | -12.8% |
| Q4 25 | 14.1% | -14.4% | ||
| Q3 25 | 15.9% | -10.3% | ||
| Q2 25 | 6.6% | -39.9% | ||
| Q1 25 | 13.3% | -46.8% | ||
| Q4 24 | -2.3% | -134.4% | ||
| Q3 24 | -13.8% | -471.8% | ||
| Q2 24 | 3.7% | -60.4% | ||
| Q1 24 | 14.8% | -85.0% |
| Q4 25 | 11.1% | -39.4% | ||
| Q3 25 | 11.7% | -14.7% | ||
| Q2 25 | 4.0% | -43.1% | ||
| Q1 25 | 8.0% | -44.9% | ||
| Q4 24 | -5.4% | -146.5% | ||
| Q3 24 | -16.3% | -522.8% | ||
| Q2 24 | -1.7% | -49.3% | ||
| Q1 24 | 13.2% | -77.0% |
| Q4 25 | $1.14 | $-2.21 | ||
| Q3 25 | $1.13 | $-0.84 | ||
| Q2 25 | $0.36 | $-2.13 | ||
| Q1 25 | $0.69 | $-1.70 | ||
| Q4 24 | $-0.45 | $-5.00 | ||
| Q3 24 | $-1.27 | $-21.58 | ||
| Q2 24 | $-0.14 | $-2.31 | ||
| Q1 24 | $0.82 | $-2.75 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $493.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $540.7M | $427.5M |
| Total Assets | $1.4B | $2.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $493.2M | ||
| Q3 25 | $262.6M | $498.6M | ||
| Q2 25 | $217.8M | $758.0M | ||
| Q1 25 | $149.8M | $651.6M | ||
| Q4 24 | $144.9M | $585.9M | ||
| Q3 24 | $145.0M | $678.8M | ||
| Q2 24 | $240.1M | $689.8M | ||
| Q1 24 | $228.6M | $680.6M |
| Q4 25 | $540.7M | $427.5M | ||
| Q3 25 | $505.8M | $479.8M | ||
| Q2 25 | $436.8M | $513.2M | ||
| Q1 25 | $418.6M | $594.2M | ||
| Q4 24 | $403.7M | $658.3M | ||
| Q3 24 | $405.9M | $930.9M | ||
| Q2 24 | $455.8M | $2.1B | ||
| Q1 24 | $452.0M | $2.2B |
| Q4 25 | $1.4B | $2.2B | ||
| Q3 25 | $1.4B | $2.2B | ||
| Q2 25 | $1.3B | $2.5B | ||
| Q1 25 | $1.3B | $2.5B | ||
| Q4 24 | $1.3B | $2.6B | ||
| Q3 24 | $1.3B | $2.8B | ||
| Q2 24 | $920.8M | $3.9B | ||
| Q1 24 | $914.5M | $4.2B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $52.6M |
| Free Cash FlowOCF − Capex | $29.1M | $43.3M |
| FCF MarginFCF / Revenue | 11.8% | 12.9% |
| Capex IntensityCapex / Revenue | 0.5% | 2.8% |
| Cash ConversionOCF / Net Profit | 1.10× | — |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $80.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $52.6M | ||
| Q3 25 | $44.1M | $25.6M | ||
| Q2 25 | $75.8M | $-7.8M | ||
| Q1 25 | $35.0M | $33.8M | ||
| Q4 24 | $15.9M | $37.8M | ||
| Q3 24 | $12.5M | $-89.3M | ||
| Q2 24 | $17.4M | $-44.8M | ||
| Q1 24 | $18.3M | $-217.0M |
| Q4 25 | $29.1M | $43.3M | ||
| Q3 25 | $38.0M | $22.8M | ||
| Q2 25 | $71.8M | $-9.1M | ||
| Q1 25 | $32.5M | $23.7M | ||
| Q4 24 | $13.5M | $25.5M | ||
| Q3 24 | $7.7M | $-136.7M | ||
| Q2 24 | $13.0M | $-67.0M | ||
| Q1 24 | $13.7M | $-243.4M |
| Q4 25 | 11.8% | 12.9% | ||
| Q3 25 | 16.7% | 6.7% | ||
| Q2 25 | 34.0% | -3.1% | ||
| Q1 25 | 16.5% | 10.8% | ||
| Q4 24 | 7.1% | 13.0% | ||
| Q3 24 | 5.2% | -58.1% | ||
| Q2 24 | 9.4% | -25.2% | ||
| Q1 24 | 10.0% | -119.1% |
| Q4 25 | 0.5% | 2.8% | ||
| Q3 25 | 2.7% | 0.8% | ||
| Q2 25 | 1.9% | 0.4% | ||
| Q1 25 | 1.3% | 4.6% | ||
| Q4 24 | 1.3% | 6.2% | ||
| Q3 24 | 3.2% | 20.1% | ||
| Q2 24 | 3.2% | 8.4% | ||
| Q1 24 | 3.3% | 12.9% |
| Q4 25 | 1.10× | — | ||
| Q3 25 | 1.66× | — | ||
| Q2 25 | 8.87× | — | ||
| Q1 25 | 2.23× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.00× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
SEDG
| Other | $197.7M | 59% |
| Europe Except Netherlands | $99.4M | 30% |
| Others | $38.2M | 11% |
